

Q-TRaCE

Qld–The Radiopharmaceutical Centre of Excellence

Department of Nuclear Medicine, Royal Brisbane and Women's Hospital

Q-TRaCE

- has a wide portfolio of radiopharmaceuticals, including theranostic pairs for diagnosis and therapy.
- holds Therapeutic Goods Administration licence.
- can distribute to any hospital or public institution in Queensland.
- has the capacity to implement new products, including novel and research radiopharmaceuticals.

Contact: Marissa Bartlett, Q-TRaCE Manager
Ph: 3646 7569
E: q-trace@health.qld.gov.au

We welcome enquiries for additional imaging or therapeutic agents.

Available for clinical use

Diagnostic Imaging

^{18}F -FDG	Glucose metabolism
^{18}F -NaF	Bone metastases
^{18}F -DOPA	Congenital hyperinsulinaemia; glioma; insulinoma; Parkinson's disease
^{18}F -FMISO	Tumour hypoxia
^{18}F -PSMA1007	Prostate cancer
^{18}F -GE180*	Neuroinflammation
^{18}F -GE216*	Alzheimer's Disease
^{68}Ga -DOTA TATE	Neuroendocrine tumours
^{68}Ga -PSMA-HBED-CC	Prostate cancer
^{68}Ga -Pentixafor	Overexpression of CXCR4 receptor
^{124}I -NaI	Thyroid cancer
$^{99\text{m}}\text{Tc}$ -based compounds	e.g. renal, cardiac, lung and bone scans

Radionuclide Therapy

^{177}Lu -DOTA TATE	Neuroendocrine tumours
^{177}Lu -PSMA-617	Prostate cancer

Coming soon

^{68}Ga -Exendin	Insulinoma
---------------------------	------------

* For use in research projects which have ethics approval